Gold/lanthanide nanoparticle conjugates and uses thereof
The present disclosure is directed generally to gold/lanthanide nanoparticle conjugates, such as gold/gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, nanoparticle conjugates conjugated to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.
1. A gold/lanthanide nanoparticle conjugate comprising:
a gold nanoparticle;
a lanthanide containing metal organic framework disposed on said gold nanoparticle; and
a polymer, polymer precursor, or initiator grafted directly onto said lanthanide containing metal organic framework.
2. The nanoparticle conjugate according to claim 1 , wherein the polymer, polymer precursor or initiator is grafted onto the lanthanide containing metal organic framework by a covalent bond or non-covalent bond from a functional group selected from the group consisting of thiolates, thioethers, thioesters, carboxylates, amines, amides, halides, phosphonates, phosphonate esters, phosphinates, sulphonates, sulphates, porphyrins, nitrates, pyridine, pyridyl based compounds, nitrogen containing ligands, oxygen containing ligands, and sulfur containing ligands.
3. The nanoparticle conjugate according to claim 2 , wherein the nanoparticle has the chemical structure of Formula (I)
wherein n is an integer; and
R 2 , R 3 , and R 4 are each independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylsulfinyl, substituted alkylsulfinyl, alkylsulfonyl, substituted alkylsulfonyl, alkylthio, substituted alkylthio, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxy, substituted aryloxy, aryloxycarbonyl, substituted aryloxycarbonyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyloxy, substituted heteroalkyloxy, heteroaryloxy and substituted heteroaryloxy.
4. The nanoparticle conjugate according to claim 3 , further comprising one or more additional functional groups.
5. The nanoparticle conjugate according to claim 4 , wherein the one or more additional functional groups are selected from the group consisting of carboxylic acids and carboxylic acid salt derivatives, acid halides, sulfonic acids and sulfonic acid salts, anhydride derivatives, hydroxyl derivatives, amine and amide derivatives, silane derivations, phosphate derivatives, nitro derivatives, succinimide and sulfo-containing succinimide derivatives, halide derivatives, alkene derivatives, morpholine derivatives, cyano derivatives, epoxide derivatives, ester derivatives, carbazole derivatives, azide derivatives, alkyne derivatives, acid containing sugar derivatives, glycerol analogue derivatives, maleimide derivatives, protected acids and alcohols, and acid halide derivatives.
6. The nanoparticle conjugate of claim 4 , further comprising an imaging agent covalently bonded to said polymer.
7. The nanoparticle conjugate of claim 6 , wherein the imaging agent is a fluorescent monomer.
8. The nanoparticle conjugate of claim 7 , wherein the fluorescent monomer is poly(fluorescein-O-methacrylate)(PFMA).
9. The nanoparticle conjugate of claim 4 further comprising a therapeutic agent covalently bonded to said polymer.
10. The nanoparticle conjugate of claim 4 further comprising a targeting agent covalently bonded to said polymer.
11. A pharmaceutical composition comprising:
a nanoparticle conjugate of claim 1 , and;
a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising:
a nanoparticle conjugate of claim 11 , and
a pharmaceutically acceptable carrier.
13. A method of diagnosing a disease or disorder comprising:
administering an effective amount of the nanoparticle conjugate of claim 1 to a patient in need of a diagnosis of said disease or disorder.
14. A method of treating a disease or disorder comprising:
administering an effective amount of the nanoparticle conjugate of claim 1 to a patient in need of treatment of said disease or disorder.
15. A method of imaging tissue comprising:
administering an effective amount of the nanoparticle conjugate of claim 1 to a patient in need of imaging;
and obtaining an image of the patient or of a portion of said patient.
16. A method of imaging tissue of claim 15 wherein the imaging technique is chosen from one or more of the group consisting of: nuclear magnetic imaging, positron emission tomography, computed x-ray tomography, dark field confocal microscopy, light field confocal microscopy, optical imaging.
17. A method of making a nanoparticle conjugate comprising:
contacting a compound of Formula (I) or Formula (II) or salt thereof with a compound of Formula (V) or a salt thereof to form the compound of Formula (VI):
contacting the compound of Formula (VI) with a gold nanoparticle disposed to a gadolinium containing metal organic framework to form the gold/gadolinium nanoparticle conjugate of claim 1 ;
wherein n is an integer, and
R 2 , R 3 , R 4 , R 7 , and R 8 are each independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylsulfinyl, substituted alkylsulfinyl, alkylsulfonyl, substituted alkylsulfonyl, alkylthio, substituted alkylthio, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxy, substituted aryloxy, aryloxycarbonyl, substituted aryloxycarbonyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyloxy, substituted heteroalkyloxy, heteroaryloxy and substituted heteroaryloxy, to form a gadolinium nanoparticle conjugate with the compounds of formula (I).
18. A method of making a nanoparticle conjugate comprising:
contacting a compound of Formula (I) or Formula (II) or salt thereof with a compound of Formula (V) or a salt thereof to form the compound of Formula (VI):
contacting the compound of Formula (VI) with a gold nanoparticle disposed to a gadolinium containing metal organic framework to form the gold/gadolinium nanoparticle conjugate of claim 1 ;
wherein n is an integer, and
R 2 , R 3 , R 4 , R 5 , and R 8 are each independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylsulfinyl, substituted alkylsulfinyl, alkylsulfonyl, substituted alkylsulfonyl, alkylthio, substituted alkylthio, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxy, substituted aryloxy, aryloxycarbonyl, substituted aryloxycarbonyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyloxy, substituted heteroalkyloxy, heteroaryloxy and substituted heteroaryloxy, to form a gadolinium nanoparticle conjugate with the compounds of formula (I).
19. The method of claim 13 , further comprising a step of contacting a reducing agent to the compound of Formula (I) before contacting said nanoparticle with said compound of Formula (I).